First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials
First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of...
China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices
The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...
Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,...
Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE
The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...
Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled...
ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development
ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic...
CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China
The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...
Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA
Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...
Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its...
CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for...
Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults
China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing...
Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion
The Beijing Municipal Medical Insurance Bureau has released a notification outlining key tasks for the...
Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that...
Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC
The Center for Drug Evaluation (CDE) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB)...
Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has announced that the...
Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
Mabwell Bioscience’s 9MW3911 Receives NMPA Approval for Clinical Trial in Advanced Tumors
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...
Akeso Biopharma Initiates Phase III Study for Ivonescimab in Non-Small Cell Lung Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the initiation of a Phase III clinical study...
Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights
China-based Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the...
Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has announced receiving market approval...